Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.05
Bid: 2.01
Ask: 2.04
Change: -0.05 (-2.41%)
Spread: 0.03 (1.493%)
Open: 2.05
High: 2.09
Low: 2.00
Prev. Close: 2.075
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: ImmuPharma waits on FDA; IDE Group waits on audit

Wed, 31st Aug 2022 21:41

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

ImmuPharma PLC - specialist drug discovery and development company - Says US partner for Lupuzor, Avion Pharmaceuticals, yet to meet US Food & Drug Administration. "The company is in close contact with Avion and have been advised that the FDA is experiencing general delays in meeting response dates and that this is not specific to Avion and the Type C meeting for Lupuzor. The company will notify the market as soon as practicable once a response from the FDA has been received," it adds.

----------

IDE Group Holdings PLC - Edinburgh-based network, cloud and IT managed services - Auditors request further time to complete work on firm's 2021 results. "The delay in publication relates to the cumulative impact of Covid, including related staff absences from Covid and the resulting knock on impact on the audit process, as previously announced," it says. Expects release before end of September. Had already delayed results, and was expecting them towards the end of July. Previously notes results are expected to show trading Ebitda of GBP3.0 million, but this could "potentially increase" as a result of various potential non-trading audit adjustments.

----------

Galantas Gold Corp - Northern Ireland-focused gold producer - Closes CAD6.9 million, about USD5.3 million, private placement, after upping fundraising with previously hoping to raise CAD4 million. Sells 14.8 million units at CAD0.45 each and further 506,667 units at same price. Each unit holds one share and one-half share warrant. Each warrant can be exchanged for one share, at CAD0.55, until February 28. "The company intends to use the net proceeds of the upsized offering for exploration and development at the Joshua Target as well as for working capital and general corporate purposes," it has previously said.

----------

Castillo Copper Ltd - Perth, Australia-based exploration company focused on copper across Australia and Zambia - Appoints two contractors for the upcoming drilling campaign at the Broken Hill Alliance project's East zone. Drilling expected to begin in fourth quarter, subject to regulatory approval from Australia's NSW resources regulator. Managing Director Dennis Jensen "delighted" with appointment of AllState and FieldCrew.

----------

Phoenix Global Resources PLC - London-based upstream oil and gas company focused on Argentina - Says shareholder holding 2% of issued capital sends letter to firm about "certain claims alleged against the company and other parties." Adds: "The board is taking legal advice in relation to the letter and believes the claims that it alleges to be without merit." Has previously proposed delisting from AIM and the Buenos Aires Stock Exchange, providing a "cash exit opportunity for shareholders" in the process. Major shareholder Mercuria Energy Group Ltd, which holds an 84% stake, proposes purchasing shares at 7.5p each under the exit opportunity, a 25% premium to its closing price on June 25, the day before it discussed a potential delisting with Mercuria. Will hold general meeting on September 1 to gain at least 75% shareholder approval for the delisting and the scheme.

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
4 Nov 2015 10:44

ImmuPharma's Lupuzor trial on track for 2017 completion

(ShareCast News) - ImmuPharma has reached a number of important milestones in the phase three clinical trial of Lupuzor. The AIM listed company provided an update to the market on Wednesday about the drug trial, its lead programme for the potential breakthrough compound for life threatening auto imm

Read more
4 Nov 2015 10:31

WINNERS & LOSERS SUMMARY: Housebuilders And Estate Agents Torn Down

Read more
4 Nov 2015 08:56

ImmuPharma Says Lupuzor Trials Set To Start In US This Year

Read more
30 Sep 2015 09:29

ImmuPharma Appoints Non-Executive Chairman As Loss Narrows

Read more
29 Jul 2015 09:16

ImmuPharma Says Chairman And Co-Founder Richard Warr Dies

Read more
27 Jul 2015 07:08

ImmuPharma Secures Financing To Continue Lupuzor Progress (ALLISS)

Read more
29 May 2015 07:28

LONDON MORNING BRIEFING: AB Foods Lifted To Buy From Sell By Goldman

Read more
29 May 2015 05:17

AGM, EGM Calendar - Week Ahead

Read more
28 May 2015 16:28

AGM, EGM Calendar - Week Ahead

Read more
6 May 2015 08:11

ImmuPharma Chairman Takes Leave To Deal With Health Issue

Read more
30 Apr 2015 09:37

Immupharma To Focus On Lupuzor, 2014 Loss Narrows On Trial End

Read more
11 Feb 2015 12:18

Immupharma Says Cancer Therapy Trial Meets Primary Objective

Read more
22 Jan 2015 12:00

UK MIDDAY BRIEFING: Royal Mail Up As It Meets Low Expectations

Read more
22 Jan 2015 11:19

UK WINNERS & LOSERS: Oxford Instruments Falls On Another Warning

Read more
22 Jan 2015 08:32

ImmuPharma Shares Up 22% On Simbec-Orion Lupuzor Agreement

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.